RxDoctor Payments Data

Jacquelyn Kirby, APRN

Nurse Practitioner · Greenville, KYNPI 1053509729

Payments from drug & device makers

$2,541in general payments, 2019–2025

Across 149 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$561
  • AbbVie$424
  • Bayer$241
  • AstraZeneca$206
  • Novo Nordisk$201
  • GSK$138
  • plus $769 from 22 others

What the payments were for

  • Food & beverage$2,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,541 in reported general payments places this provider in the 80th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$569
Medicare patients
25
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$105,422
FarxigaDapagliflozin Propanediol103$84,971
JanuviaSitagliptin Phosphate80$54,047
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$53,634
RybelsusSemaglutide45$50,029
MounjaroTirzepatide41$42,117
OzempicSemaglutide24$30,487
EliquisApixaban37$28,945
XareltoRivaroxaban21$26,729
TrulicityDulaglutide18$23,522
Tresiba Flextouch U-100Insulin Degludec20$23,269
Breo ElliptaFluticasone/Vilanterol38$19,048
VraylarCariprazine Hcl13$18,784
VascepaIcosapent Ethyl29$11,292
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$9,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$13$105,422124 claims
AstraZenecaFarxiga, Brilinta$206$89,962115 claims
Novo NordiskRybelsus, Ozempic$201$80,51669 claims
GSKTrelegy Ellipta, Breo Ellipta$138$72,682107 claims
Lilly USA, LLCMounjaro, Trulicity$138$65,63859 claims
MerckJanuvia$12$54,04780 claims
PfizerEliquis$34$28,94537 claims
AbbVieVraylar, Linzess, Synthroid$424$27,71046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Greenville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →